; findings. Sec. 2. Cognitive impairment detection benefit in the Medicare annual wellness visit and initial preventive physical examination. Sec. 3. Medicare quality payment program. Sec. 4. Report to Congress on implementation. (c) Findings Congress finds the following: (1) It is estimated that 5,800,000 million Americans are living with Alzheimer's disease in 2019. This includes an estimated 5,600,000 million people age 65 and older and approximately 200,000 individuals under age 65 who have younger-onset Alzheimer's. By 2050, the number of people age 65 and older with Alzheimer’s dementia is projected to increase to 13,800,000 Americans. (2) As many as half of the estimated 5,100,000 American seniors with Alzheimer’s disease and other dementias have never received a diagnosis. (3) In 2019, it is expected that Alzheimer’s and related dementias will cost Medicare and Medicaid $195,000,000,000. By 2050, it is estimated that overall Alzheimer’s costs will increase to more than $1,100,000,000,000. (4) Alzheimer’s exacts an emotional and physical toll on caregivers, resulting in higher incidence of heart disease, cancer, depression, and other health consequences. (5) Alzheimer’s disease disproportionately impacts women and people of color. Women are twice as likely to develop Alzheimer's as they are breast cancer. African Americans are about 2 times more likely than White Americans to have Alzheimer's disease and other dementias. Latinos are about 1 1/2 times more likely than White Americans to have Alzheimer’s disease and other dementias. According to the Centers for Disease Control, among people ages 65 and older, African Americans have the highest prevalence of Alzheimer’s disease and related dementias (13.8 percent), followed by Hispanics (12.2 percent), and non-Hispanic Whites (10.3 percent), American Indian and Alaska Natives (9.1 percent), and Asian and Pacific Islanders (8.4 percent). This higher prevalence translates into a higher death rate: Alzheimer's deaths increased 55 percent among all Americans